The Food and Drug Administration is moving to dismantle one of the most persistent barriers to affordable medicine in the United States: the slow approval of generic versions of biological drugs. These complex therapies, developed from living cells rather than chemicals, have long been both the pharmaceutical industry’s most prized
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day
